1h Free Analyst Time
Ischemia Reperfusion Injury - Pipeline Review, H2 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2020, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.
Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 33 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 1 molecules, respectively.
Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionIschemia Reperfusion Injury - Overview
Ischemia Reperfusion Injury - Therapeutics Development
Ischemia Reperfusion Injury - Therapeutics Assessment
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
Ischemia Reperfusion Injury - Drug Profiles
Ischemia Reperfusion Injury - Dormant Projects
Ischemia Reperfusion Injury - Discontinued Products
Ischemia Reperfusion Injury - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Ischemia Reperfusion Injury, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Acelerox LLC, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Apollo Therapeutics LLC, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Aptorum Group Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Argenx SE, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Axolo Pharma Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Balmes Transplantation SAS, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Beijing Northland Biotech Co Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Celdara Medical LLC, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Cellmid Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by CFM Pharma Holding BV, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Cypralis Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Domainex Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by EVAS Therapeutics LLC, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Everon Biosciences Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Gero Discovery, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by LG Chem Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Limulus Therapeutics Pty Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Mallinckrodt Plc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Neuroene Therapeutics LLC, H2 2020
- Ischemia Reperfusion Injury - Pipeline by New B Innovation Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by New Horizons Pharma Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Nour Heart Therapeutics LLC, H2 2020
- Ischemia Reperfusion Injury - Pipeline by NuNerve Pty Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Orion Corp, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Pfizer Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Proteo Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Radikal Therapeutics Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Revive Therapeutics Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Corp, H2 2020
- Ischemia Reperfusion Injury - Pipeline by TheraSource LLC, H2 2020
- Ischemia Reperfusion Injury - Pipeline by United Therapeutics Corp, H2 2020
- Ischemia Reperfusion Injury - Pipeline by Young Therapeutics LLC, H2 2020
- Ischemia Reperfusion Injury - Dormant Projects, H2 2020
- Ischemia Reperfusion Injury - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Ischemia Reperfusion Injury - Dormant Projects, H2 2020 (Contd..2), H2 2020
- Ischemia Reperfusion Injury - Dormant Projects, H2 2020 (Contd..3), H2 2020
- Ischemia Reperfusion Injury - Dormant Projects, H2 2020 (Contd..4), H2 2020
- Ischemia Reperfusion Injury - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Ischemia Reperfusion Injury, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acelerox LLC
- Amyndas Pharmaceuticals LLC
- Angion Biomedica Corp
- Apollo Therapeutics LLC
- Aptorum Group Ltd
- Argenx SE
- Axolo Pharma Inc
- Balmes Transplantation SAS
- Beijing Northland Biotech Co Ltd
- Bolder Biotechnology Inc
- Celdara Medical LLC
- Cellmid Ltd
- CFM Pharma Holding BV
- Corline Biomedical AB
- Cypralis Ltd
- Domainex Ltd
- EVAS Therapeutics LLC
- Everon Biosciences Inc
- Gero Discovery
- Gilead Sciences Inc
- Glucox Biotech AB
- Ischemix Inc
- Lee's Pharmaceutical Holdings Ltd
- LG Chem Ltd
- Limulus Therapeutics Pty Ltd
- Mallinckrodt Plc
- Neuroene Therapeutics LLC
- New B Innovation Ltd
- New Horizons Pharma Inc
- Nour Heart Therapeutics LLC
- NuNerve Pty Ltd
- Orion Corp
- Pfizer Inc
- Pharming Group NV
- Proteo Inc
- Radikal Therapeutics Inc
- Reata Pharmaceuticals Inc
- Revive Therapeutics Ltd
- SBI Pharmaceuticals Co Ltd
- Stealth BioTherapeutics Corp
- TheraSource LLC
- United Therapeutics Corp
- Young Therapeutics LLC
